8-K filing — Vistagen Therapeutics, Inc. (VTGN)
Filed: 2026-09-25 AccNo: 0001628280-26-063510 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Vistagen Says Fasedienol Well-Tolerated Up To 12 Months In Preliminary Open-Label Extension Of Phase 3 Social Anxiety Trial; Plans FDA Meeting This Quarter On New Phase 3
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Vistagen shares are trading lower. The company announced it presented exploratory data at Psych Congress 2026 highlighting potential efficacy signal for fasedienol nasal spray in patients with severe social anxiety disorder.
Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.